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Norman Arnheim1,4,*
Noonan syndrome (NS) is among the most common Mendelian genetic diseases (~1/2,000 live births). Most cases (50%–84%) are spo-
radic, and new mutations are virtually always paternally derived. More than 47 different sites of NS de novo missense mutations are
known in the PTPN11 gene that codes for the protein tyrosine phosphatase SHP-2. Surprisingly, many of these mutations are recurrent
with nucleotide substitution rates substantially greater than the genome average; the most common mutation, c.922A>G, is at least
2,400 times greater. We examined the spatial distribution of the c.922A>G mutation in testes from 15 unaffected men and found
that the mutations were not uniformly distributed across each testis as would be expected for a mutation hot spot but were highly clus-
tered and showed an age-dependent germline mosaicism. Computational modeling that used different stem cell division schemes
confirmed that the data were inconsistent with hypermutation, but consistent with germline selection: mutated spermatogonial
stem cells gained an advantage that allowed them to increase in frequency. SHP-2 interacts with the transcriptional activator STAT3.
Given STAT3’s function inmouse spermatogonial stem cells, we suggest that this interactionmight explain themutant’s selective advan-
tage by means of repression of stem cell differentiation signals. Repression of STAT3 activity by cyclin D1 might also play a previously
unrecognized role in providing a germline-selective advantage to spermatogonia for the recurrent mutations in the receptor tyrosine
kinases that cause Apert syndrome and MEN2B. Looking at recurrent mutations driven by germline selection in different gene families
can help highlight common causal signaling pathways.Introduction
Noonan syndrome (NS [MIM 163950]) is one the most
commonMendelian disorders.1,2 NS features include char-
acteristic craniofacial abnormalities, short stature, heart
defects, intellectual disability and delay, and a variety of
other anomalies, as well as a predisposition to certain can-
cers. NS is transmitted in an autosomal-dominant fashion
in families but a sizable proportion of cases result from new
mutations originating in the germline of the normal
father.3 NS mutations can arise in several different genes
but mutations in PTPN11 [MIM 176876], the gene encod-
ing the protein tyrosine phosphatase nonreceptor type 11
(SHP-2), are the most frequent contributors. PTPN11 is
expressed ubiquitously and plays an important role in
animal development.4–6
There are many possible disease-causing missense muta-
tion sites in PTPN11 (~47) that cause NS; surprisingly,
many of these sites show recurrent mutation.7,8 The
most common mutation is c.922A>G (p.Asn308Asp).1,9
We conservatively calculate (disease incidence1 3 percent-
age of sporadic cases10–12 3 percentage of PTPN11 muta-
tions1,9 3 percentage of c.922A>G1,9) that the de novo
mutation frequency of the 922A>G mutation exceeds
the genome average A>G mutation frequency by more
than 2,400 fold. Further, the average age of fathers of1Molecular and Computational Biology Program, University of Southern Ca
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The AmNS children is greater than the average of fathers in
the general population, consistent with a paternal age
effect.3
We use the term RAMP for such disease-causing muta-
tions that are recurrent, transmitted as autosomal domi-
nant, male-biased, and have a paternal age effect. Other
examples are the mutations that cause achondroplasia
[MIM 100800], Apert syndrome [MIM 101200], and multi-
ple endocrine neoplasia type 2B (MEN2B [MIM 162300]).
In this paper, we use a testis dissection and mutation
detection strategy we developed previously13–15 to study
the spatial distribution of the NS mutation in unaffected
men of different ages. Further, we test several computa-
tional models of self-renewing Ap spermatogonial (SrAp)
stem cell division patterns to see how this high incidence
of sporadic cases due to recurrent mutation is achieved.
Finally, we provide insights into the possible biochemical
basis for a germline selective advantage.Material and Methods
Source of Testes
Testes came from unaffected donors (NDRI, Philadelphia, PA) not
treated with drugs that interfere with normal spermatogenesis and
were frozen 10–12 hr after death. Procedures followed the ethical
standards of the Institutional Review Board of the University oflifornia, Los Angeles, CA 90089-2910, USA; 2Mindich Child Health and
ences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place,
y of Human Genetics. All rights reserved.
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Southern California and the relevant National Institutes of Health
guidelines.
Testis Dissection
Details of the dissections, DNA isolation, and quantitation of the
amount of DNA in each testis piece have been published.13–15
c.922A>G Mutation Frequency Assay
We used our modification of a highly sensitive allele-specific PCR
assay (pyrophosphorolysis-activated PCR16) with single-molecule
sensitivity.13–15 Based on an analysis of 3.3 3 108 control
genomes, the false-positive rate of this assay is 9.3 3 107. Each
reaction contained 20 mM HEPES (pH 7.6), 30 mM KCl, 50 mM
Na4PPi, 2 mM MgCl2, 80 mM of each dNTP, 2 mM Rox, 0.23 Syber
Green I, 0.04 units/uL TMA31FS DNA polymerase (see Acknowl-
edgments), DNA containing 25,000 genomes from the testis piece
and 160 nM of each primer. The c.922A>G mutation-specific
primer sequences (Biosearch) were 50 TGATCCCAATGAGCCTG
TTTCAGATTACATCAATGCAGdd 3
0 and 50 GAAAACACTGTGAAA
AGCAAAGCTTACCATGATGATATCdd 3
0.
The cycling conditions were initial denaturation 2 min, 94C,
and then 50 cycles of 6 s at 94C and 40 s at 71C followed by
90 cycles of 6 s at 94C and 65 s at 71C.
Mutation Counting Strategy
We estimated the c.922A>G mutation frequency by using ten
reactions (25,000 genomes per reaction) from every testis piece.
If less than half were positive, the analysis was repeated at a 1:30
sample dilution. If no mutation was found, we took the number
from the initial experiment as an estimate of the mutation fre-
quency (after Poisson correction). If five or more of the original
reactions were positive, we repeated the experiment by using
diluted samples of the testis piece until fewer than 50% were pos-
itive. The presence of a singlemutantmolecule in any reactionwas
detected by quantitative PCR and its melting profile.15 Twenty
negative controls each contained 25,000 human blood DNA
genomes (Promega). Twenty positive controls each contained the
same amount of blood genomes plus an average of one genome
of DNA from an individual carrying the c.922A>G mutation.
Statistical Testing
The estimate of the average testis mutation frequency (Av) is the
average of the frequencies of the testis pieces weighted by the
number of genomes (see Table S1 available online) in those pieces.
Our general computational strategy is that we find the model
parameters that match the observed Av for each testis and then
simulate the model with these parameters such that we have
one million simulations with an Av within 5% of the Av observed
for that testis. For these simulations, we test whether the simulated
summary statistics (specifically Mx/Av and F < 50, which are
defined in Results) are as great as the statistics observed in the testis
data. The p values in Tables 2, 3, S2, and S3 have not been cor-
rected for multiple tests. In this paper, we have performed 120 sta-
tistical tests: 15 testes 3 4 models 3 2 summary statistics. Because
almost all of the p values in Table 2 are less than 106, both the
asymmetric and symmetric hot-spot models are still strongly re-
jected after a Bonferroni multiple test correction. In Table 3, the
single uncorrected p value of 0.01 is not low enough to reject
the model after the Bonferroni multiple-test correction. In Web
Resources, we provide a link to the computer code to simulate
all of the models we test.918 The American Journal of Human Genetics 92, 917–926, June 6, 2Results
We divide the testes of 15 unaffected men each into 192
approximately equal pieces (first we cut each testis into
six slices, then we further divide each slice into 32 pieces),
and measure the c.922A>G mutation frequency in each
testis piece. In Figure 1, the mutation frequencies for
each testis piece (measured in units of mutations per
million genomes, or pmg) are represented by colors
ranging from light gray to dark brown. Note that the distri-
bution of mutations in most testes appears clustered and
not uniform as would be expected if the c.922A disease
site were hypermutable.13–15 The mutation frequencies
for all of the testis pieces are listed in Table S1.
In Table 1, we use several statistics to summarize both
the mutation frequency and their clustering. For each
testis, we consider the average mutation frequency of all
of the testis pieces (Av). Because most of the mutations
are clustered in a small number of testis pieces, we also
consider the testis piece with the maximum mutation fre-
quency (Mx). To normalize for the different testes’ average
frequencies, we compute the ratio of Mx to Av (Mx/Av).
Most of the pieces in any testis have relatively low fre-
quencies. Thus for each testis we also calculate the fraction
(F< 50) of testis pieces withmutation frequencies less than
50 pmg (colored light or dark gray in Figure 1) as another
measure of clustering.
The youngest age group consists of testes from four indi-
viduals with ages ranging from 19 to 23 years. For all of the
testes in this age group, there are relatively few mutations:
both the Av andMx values are low. The middle-aged group
contains five testes from donors ranging in age from 36 to
62 years. All of these testes have high mutation fre-
quencies, and the mutations are clustered: the Av values
are high, the Mx values are much greater still, yet most
of the testis pieces have low mutation frequencies indi-
cated by the F < 50 fractions near 90%. Six testes from
individuals ranging in age from 68 to 80 years comprise
the oldest age group. This age group is heterogeneous
because some of the testes are similar to those in the youn-
gest age group, whereas others are like those in the middle-
aged group. As a control, we previously showed for two
middle-aged testes that mutations at a nondisease CpG
site on another chromosome had no mutation clusters
but rather a uniform distribution and each testis piece
exhibited a low mutation frequency.15
Hot-Spot Models
We test two different hot-spot models (so named because
the mutation rate per cell division at the disease site can
be substantially greater than the genome average) with
two different adult SrAp cell-division schemes (asym-
metric17,18 and symmetric19–21). Simulations of the asym-
metric hot-spot model13–15 (described in Figure 2A), do
not produce the extreme mutation clusters observed in
the testes; rather, the mutations are relatively uniformly
distributed. Table 2 shows that this model is strongly013
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Figure 1. Testis Data Obtained from 15 Unaffected Donors of Various Ages
Each testis is cut into six slices (left to right), and each slice is further divided into 32 pieces (four pieces wide and eight pieces long). The
frequency of the Noonan syndrome PTPN11 c.922A>G mutation is measured in each testis piece in units of mutants per million
genomes (pmg). The data in the left column are from the testes of the youngest age group; all the testis pieces have low-mutation fre-
quencies. The data in the middle column are from the testes of the middle-age group; the mutations are clustered. The data in the right
column are from the testes of the oldest age group; these testes are heterogeneous as some are like those in the youngest age group while
others are similar to those in the middle-age group.rejected (p value < 106) for all of the middle-aged testes.
As an example, consider testis 374-2 from a 62-year-old
donor. For those simulations of the asymmetric hot-spot
model with Av values within 5% of that observed in this
testis, the 95% range of the Mx/Av ratio is between 1
and 7. However, the Mx/Av ratio observed in the testis is
much greater at 62. In fact, in one million simulations of
this model, none of the Mx/Av ratios is as great as is
observed in the testis; therefore, the asymmetric hot-spot
model is rejected with a p value less than 106.The AmThe symmetric hot-spot model14 (Figure 2B) shows
slightly more evidence of clustering than the asymmetric
hot-spot model. For example, for testis 374-2 the 95%
range of the Mx/Av ratio is between 4 and 9. However,
like the hot-spot model, this range is substantially lower
than the value observed in the testis, and we also strongly
reject the symmetric hot-spot model (p value < 106).
Table 2 shows that the results are similar for the F< 50 frac-
tion statistic, and for the other middle-aged testes. In Table
S2, we show that both hot-spot models are also rejected forerican Journal of Human Genetics 92, 917–926, June 6, 2013 919
Table 1. Summary of Testis Data
Testis Age Ava (pmgb) Mxc (pmg) Mx/Avd F < 50e (%)
59056 19 0.8 32 39 100
63878 21 9 73 8 99
63205 21 0.2 8 40 100
60832 23 0.6 20 33 100
62923 36 172 22,306 130 90
59089 45 23 712 31 93
854-2 54 1,338 208,210 156 77
374-1 62 256 33,081 129 90
374-2 62 63 3,849 62 94
60891 68 5 76 14 95
64302 75 59 1,018 17 90
60954 76 112 1,986 18 81
60955 76 0.3 40 124 100
57650 80 52 385 7 76
60507 80 14 119 8 97
aAv, average testis mutation frequency.
bpmg, mutants per million genomes.
cMx, maximum testis piece mutation frequency.
dMx/Av, normalization to compare different testes.
eF < 50, fraction of testis pieces with mutation frequencies less than 50 pmg.those testes in the oldest age group with substantial muta-
tion clusters.
Selection Models
The two selection models are based on the cell-division
schemes of the two hot-spot models, but the mutated
SrAp gain a new function encouraging cluster formation
that is absent from the wild-type (WT) SrAp. Table 3 shows
that the asymmetric selection model13–15 (Figure 2C) is
consistent with the data from the middle-aged testes. As
an example, again consider testis 374-2. If the probability
that the mutated SrAp divide symmetrically is 0.0095,
then the 95% range of the Mx/Av ratio is between 33
and 135. Because the Mx/Av ratio observed in this testis
is 62, the asymmetric selection model is consistent with
the data.
We propose a symmetric selection model (Figure 2D) in
this paper. For testis 374-2, if the probability of a symmetric
self-renewal division for the mutated SrAp is 0.5028 (and
the probability of differentiation is 0.4972), then the 95%
range of the Mx/Av ratio is between 32 and 127. Because
this range contains the valueobserved in the testis, the sym-
metric selection model is also consistent with the data.
Table 3 shows that the results are similar for the F< 50 frac-
tion, and for the other middle-aged testes.
Age Effects
In Table S3, we show that both selection models are also
consistent with the testes from the youngest and oldest920 The American Journal of Human Genetics 92, 917–926, June 6, 2age groups. With model parameters similar to those
inferred for the middle-aged testes, the selection models
predict low mutation frequencies for the testes from
the youngest age group as a result of the lower number
of adult-phase divisions that they have experienced.
The heterogeneity in the oldest age group was previously
observed for the MEN2B mutation14 and was accounted
for in that publication, as well as this one by incorpo-
rating age-dependent cell death into the model. Sup-
porting this modeling inclusion, the number of SrAp
has been measured to decrease as men age, with most
of this decrease occurring after age 60.23,24 More-
over, because we performed the experiments for the NS
and MEN2B mutations on the same testes, we can now
report that there is one testis from the oldest age group
with NS mutation clusters but few MEN2B mutations
and another older testis with few NS mutations but
MEN2B mutation clusters (as well as older testes that
have both NS and MEN2B mutation clusters, and older
testes that have few NS and MEN2B mutations). This
diversity indicates that the mutation clusters for the
different mutations originate and evolve independently
of each other.Discussion
Our testis dissection and mutation detection experiments
reveal that the NS c.922A>G PTPN11 mutation frequency
inmiddle-age testis donors is substantially greater than the
genome average. However, the testis experiments also
reveal something that could not be learned from epidemi-
ological data, namely, that the mutations are highly clus-
tered in the testes. The challenge for the modeling was to
explain both the average mutation frequency and the clus-
tering.Modeling
The hot-spot models are an attempt to explain the elevated
mutation frequency by assuming that the mutation rate
per cell division at the disease site is substantially greater
than the genome average. Both the asymmetric and the
symmetric hot-spot models are strongly rejected (p values
less than 106) because they cannot reproduce the extreme
mutation clustering observed in the testes. The symmetric
hot-spot model, unlike the asymmetric hot-spot model,
allows for the possibility for mutation clusters to grow in
the adult but these clusters can also diminish and even
die out when SrAp cells differentiate rather than divide
symmetrically. When we tested this model, it was not
consistent with the testis data even under varying proba-
bilities of symmetric division and differentiation events
(Table S4).
In addition to varying the cell division scheme, we
have considered other modifications to the hot-spot
models. For example, it is conceivable that the overall
mutation rate increases as men age, possibly due to a013
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Figure 2. Self-Renewing Ap Spermatogonial Stem Cell (SrAp) Division Models
In each cartoon, time advances from left to right: the growth phase (zygote formation to puberty) is shown on the left and the adult
phase (after puberty) on the right. In all of the models, the growth phase divisions are symmetric (only three generations are depicted,
but in the actual model there are 30 growth phase generations). The black lines represent WT SrAp lineages, each red lightning bolt
indicates a single mutation event, and the red lines represent mutated SrAp lineages. The circles represent SrAp cells (colored red or black
depending on whether they are mutated or not, respectively) present when the testis is studied. For the symmetric division models, if a
SrAp undergoes differentiation, then that lineage is terminated (the black or red lines are not further extended). The models differ in the
types of divisions in the adult phase; in all models, these divisions occur every 16 days.22
(A) The asymmetric hot-spot model. A single mutation in the growth phase (bottom half) produces a mutation cluster. The adult-phase
divisions are asymmetric, producing one SrAp (self-renewal) and one differentiated cell (B spermatogonia, not pictured). Single muta-
tions in the adult phase (top lineage) do not produce mutation clusters. This model has one parameter: the mutation rate per cell
division.
(B) The symmetric hot-spot model. Half of the adult phase divisions are symmetric, producing two SrAp cells, while half of the adult
phase divisions produce only differentiated cells (not pictured), thus ending those stem cell lineages. Mutations in the adult phase
can randomly grow into mutation clusters (top lineage), but these clusters can also randomly diminish and even die out (lower part
of the figure). This model has one parameter: the mutation rate per cell division.
(C) The asymmetric selectionmodel. Mutated SrAp in the adult phase (unlikeWT SrAp) occasionally divide symmetrically, thus produc-
ing mutation clusters. On average, earlier mutations in the adult phase (third lineage from the bottom) produce larger clusters than later
mutations (top lineage). This model has two parameters: the mutation rate per cell division and the selection parameter p (mutated SrAp
divide symmetrically with probability p).
(D) The symmetric selectionmodel. Mutated SrAp in the adult phase (unlikeWT SrAp) have a slight preference for self-renewal divisions
over differentiation, increasing the chance for cluster formation (top lineage and lower part of the figure). This model has two param-
eters: the mutation rate per cell division and the selection parameter p (mutated SrAp divide symmetrically with probability 0.5þp, and
differentiate with probability 0.5p).
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Table 2. Hot-Spot Models Rejected for All Middle-Aged Testes
Testis Age
Model Parameter Mx/Av F < 50 (%)
Mutation Rate per Cell Division Data Simulated 95% Range p Value Data Simulated 95% Range p Value
Asymmetric hot-spot model
62923 36 3.1 3 107 130 1 – 9 <106 90 0 – 0 <106
59089 45 2.9 3 108 31 1 – 9 <106 93 99 – 100a 1.00
854-2 54 1.4 3 106 156 1 – 5 <106 77 0 – 0 <106
374-1 62 2.2 3 107 129 1 – 7 <106 90 0 – 0 <106
374-2 62 5.3 3 108 62 1 – 7 <106 94 0 – 1 <106
Symmetric hot-spot model
62923 36 3.1 3 107 130 2 – 9 <106 90 0 – 2 <106
59089 45 2.9 3 108 31 5 – 13 8 3 104 93 84 – 90a 1 3 104
854-2 54 1.4 3 106 156 1 – 5 <106 77 0 – 0 <106
374-1 62 2.2 3 107 129 2 – 6 <106 90 0 – 1 <106
374-2 62 5.3 3 108 62 4 – 9 <106 94 47 – 58 <106
aTestis 59089 is the only middle-aged testis with Av less than 50 pmg (23 pmg), so it is not surprising that the range of F < 50 values in the simulations is higher
than for the other testes.decrease in the efficiency of DNA repair.25 Such a change
would contribute to the paternal age effect; however, the
additional mutations would be spatially uniform and
not clustered in the testes. Also, the estimate of the SrAp di-
vision rate22 might be incorrect, or this rate might change
with age. Although such changes could alter the inferred
value of the mutation rate per cell-division model param-
eter, it would not lead to mutation clusters. We have not
been able to successfully modify the hot-spot models to
make them consistent with the extreme clustering we
observe in the testes, neither with these proposals nor
with previously considered modifications.13–15
A different type of model incorporates selection where a
mutated SrAp gains a new function encouraging cluster for-
mation that is absent fromWT SrAp. Both the asymmetric
and the symmetric selection models employ a similar
form of selection: in the asymmetric model the mutated
SrApoccasionally divide symmetrically, and in the symmet-
ric model the SrAp are slightly more likely to divide sym-
metrically than to differentiate. We have also considered
other forms of selection; for example, mutated SrAp might
divide more quickly or be less likely to die than WT SrAp,
but these other forms of selection cannot explain themuta-
tion clustering under biologically realistic conditions.
Both selectionmodels we use in this paper are consistent
with the testis data. Moreover, the inferred mutation rates
per cell division are what we expect for a neutral site at the
genome average,13–15 demonstrating that high mutation
frequencies can be produced by selection rather than
hypermutation.
Molecular Analysis of Germline Selection
The NS mutation we studied is the most extreme example
yet of a de novo recurrent base substitution that enters the922 The American Journal of Human Genetics 92, 917–926, June 6, 2human population each generation not because of hyper-
mutation but through germline selection. SHP-2 affects
signaling by removing phosphate groups from phosphory-
lated tyrosines of specific target proteins and is itself
activated by its binding to phosphorylated tyrosines on
receptor tyrosine kinases and other proteins.4–6 This can
lead to both the enhancement and inhibition of different
signaling pathways. This includes positive regulation
of RAS/MAPK (mitogen activated protein kinase), PI3K
(phosinositide-3-kinase)/AKT, and SFK (src family kinases)
signaling and also negative regulation of STAT3 (signal
transducer and activator of transcription 3 [MIM
102582]) signaling.5,26,27
We are not aware of any published reports directly exam-
ining SHP-2’s role in the self-renewal of mouse spermato-
gonial stem cell (SSC) cultures or in testes. The NS mutant
protein could be contributing to germline selection
through any one or a combination of perturbations to
the normal signaling of these pathways. However, the
STAT3 pathway is of special interest given its known role
in mouse SSC function.
Self-renewal of SSC must be accompanied by the differ-
entiation of SSC for sperm production and these events
should be equally balanced throughout a male’s life. Inter-
estingly, STAT3 signaling in mouse SSC plays an important
role in the differentiation step.28,29 For example, inhibiting
STAT3 activity with Stat3-specific small hairpin RNAs in
mouse SSC cultures increased SSC self-renewal but not gen-
eral spermatogonial proliferation. When these altered SSC
were transplanted into germ cell-free testes, they prolifer-
ated but failed to produce the differentiated stages typical
of normal spermatogenesis.
A specific interaction between the STAT3 and SHP-2
proteins therefore is of exceptional interest to germline013
Table 3. Selection Models Consistent with the Data for All Middle-Aged Testes
Testis Age
Model Parameters Mx/Av F < 50 (%)
Mutation Rate per Cell
Division
Selection
Parameter Data
Simulated 95%
Range p Value Data
Simulated 95%
Range p Value
Asymmetric selection model
62923 36 3.7 3 1011 0.022 130 37 – 157 0.09 90 90 – 97 0.96
59089 45 9.6 3 1011 0.011 31 20 – 72 0.64 93 88 – 94 0.10
854-2 54 1.3 3 1011 0.015 156 39 – 171 0.06 77 89 – 97 1.00
374-1 62 1.6 3 1011 0.011 129 39 – 164 0.12 90 90 – 97 0.97
374-2 62 2.6 3 1011 0.0095 62 33 – 135 0.56 94 90 – 96 0.33
Symmetric selection model
62923 36 5.9 3 1010 0.0078 130 34 – 140 0.04 90 88 – 96 0.86
59089 45 3.4 3 109 0.0024 31 16 – 55 0.34 93 86 – 92 0.01
854-2 54 9.2 3 1011 0.0064 156 46 – 190 0.15 77 92 – 99 1.00
374-1 62 4.0 3 1010 0.0038 129 38 – 160 0.11 90 90 – 97 0.96
374-2 62 7.9 3 1010 0.0028 62 32 – 127 0.49 94 89 – 96 0.23selection. Studies of nongermline adult mouse cells have
suggested that STAT3 signaling is negatively regulated by
SHP-2.27 In this same nongermline system, the function
of the hyperactivated NS p.Asn308Asp allele of SHP-2
that we studied was shown to enhance this negative regu-
lation of STAT3.27 If this type of regulation is also found in
SrAp cells, further lowering STAT3 signaling by this mutant
SHP-2 could result in a subtle bias toward stem cell self-
renewal divisions over events leading to differentiated
cells, providing a possible explanation for the germline
selective advantage.
STAT3 and Receptor Tyrosine Kinase Connections
Apert syndrome is a form of craniosynostosis, and MEN2B
is characterized by aggressive thyroid cancer and variable
penetrance of hyperplasia or tumors in the adrenal glands.
Apert syndrome is dominated by recurrent c.755C>G
(p.Ser252Trp) and c.758C>G (p.Pro253Arg) mutations in
the receptor tyrosine kinase gene fibroblast growth factor
receptor II (FGFR2 [MIM 176943]).30 The recurrent
MEN2B mutation c.2943T>C (p.Met918Thr) arises in
the receptor tyrosine kinase gene RET (‘‘rearranged during
transfection’’ proto-oncogene [MIM 164761]).31 By using
the testis dissection and mutation detection method, we
previously showed that each of these three RAMP disease
sites also do not undergo hypermutation but rather that
the unexpectedly high mutation rate per generation
appears to be the consequence of germline selection.13–15
A study by others on one of the two Apert syndrome
mutations using sperm samples also proposed selection
over hypermutation.32
Activation of both the normal RET and FGFR2 receptor
kinases have been shown to play a critical role in mouse
SSC self-renewal mediated by the PI3K/AKT, SFK, and
RAS/MAPK signaling pathways.33–36 The Apert syndromeThe Amand MEN2B disease mutations result in hyperactivation
of the FGFR2 and RET receptor tyrosine kinase downstream
signaling pathways, respectively.37–41 Interestingly, there
might be a connection between STAT3 inhibition and the
germline selective advantage provided by the Apert syn-
drome and MEN2B mutations. Studies on self-renewal in
genetically modified mouse germline stem cell cultures in
the presence of the growth factors required for self-renewal
examined the roles of activating H-ras mutations and four
cyclin proteins important for the progression of the cell
cycle including cyclin D1 (G1/S-specific cyclin D1,
CCND1 [MIM 168461]).42 These authors concluded that
there is a complicated relationship among the different
cyclins regarding their contribution to SSC self-renewal
but suggested a role for CCND1 in directing SSC toward
the differentiation pathway. This is relevant to our discus-
sion because it has been found that CCND1 can represses
the synthesis of STAT3 protein, as well as bind to STAT3
to inhibit its activity in nongermline cells.43
Based on our interpretation of the NS, Apert syndrome
and MEN2B results we propose that an important contri-
bution to establishing a germline selective advantage
might be repression of stem cell differentiation pathways
rather than simply activation of self-renewal signals as
has been previously emphasized.14,44 The construction of
mouse SSC cell lines grown in chemically defined media
and carrying the RAMP mutants we studied could be
used to examine the biochemical effects of these muta-
tions on SSC signaling, especially with regards to the role
of STAT3 and CCND1.
Other PTPN11 Mutations
Excluding the NS mutation we studied, we calculate that
19 (37%) of the ~47 other PTPN11 codons with NS disease
mutations7 are highly recurrent with frequencies rangingerican Journal of Human Genetics 92, 917–926, June 6, 2013 923
from 240 to 720 times greater than the expected genome-
wide mutation frequency (based on their relative
frequency to that of the p.Asn308Asp mutation7). If a sub-
stantial fraction of these 19 mutations were also found to
produce mutation clusters, it would suggest that the major
mutational contributions to this common Mendelian dis-
order might be based on germline selection. Although
this idea is appealing, PTPN11 mutations that produce a
different disease must also be considered (LEOPARD syn-
drome [MIM 151100]). The two most common LEOPARD
syndrome mutations (c.836A>G [p.Tyr279Cys] and
c.1403C>T [p.Thr468Met]) have a recurrence rate approx-
imately one-third that of the c.922A>G NS mutation7 and
are candidates for a germline selection-mediated RAMP
phenotype. However, these two LEOPARD syndrome
mutations are dominant negative compared to the gain-
of-function NS mutations.45 Can a germline selective
advantage be explained by either a dominant-negative or
a gain-of-function mutation? The fact that there are
many overlapping clinical features of LEOPARD syndrome
and NS supports this possibility and plausible explanations
have been suggested.45 Only experimentation in sper-
matogonial stem cell lines will be able to answer this
question definitively most likely by using mouse SSC or,
eventually,46–48 pure cultures of human spermatogonial
stem cells.
Impact of Germline Selection
Germline selection can explain the RAMP features present
in NS, Apert syndrome, and MEN2B: the recurrent high
mutation frequency, male mutation bias, and paternal
age effect.3,14,25,44,49 That some mutations might have a
positive selective advantage in the germline and yet pro-
vide a selective disadvantage to individuals who inherit
them was considered by Hastings.50 Germline selection
acts to increase the frequency at which a new mutation
enters the population each generation significantly
beyond that expected by its mutation rate per cell division,
thereby disproportionately increasing the population’s
mutational load. There are now documented cases of
four such human mutations at three loci that appear to
be examples of this phenomenon.Supplemental Data
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